Fact checked by Jennifer Klump The first “biological missile" drug that was approved to treat breast cancer just got a step ...

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the ...

Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive ...

AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line ...

Analysts at Leerink Partners said in a Monday note that DESTIN-Breast09’s findings “could support an approval” for Enhertu in ...

In the Phase III DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) and Perjeta (pertuzumab) significantly improved ...

These results are important because many patients with metastatic breast cancer do not live long enough to receive a second line of treatment. Enhertu is an antibody drug conjugate (ADC ...

AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their antibody drug conjugate ...

AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a ...

AstraZeneca has warned that countries must buy more of its cutting-edge medicines or jobs and investment will shift abroad.

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...